{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:14:13Z","timestamp":1785420853070,"version":"3.56.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101017453"],"award-info":[{"award-number":["101017453"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000740","name":"University of St Andrews","doi-asserted-by":"publisher","award":["Sanctuary scholarship"],"award-info":[{"award-number":["Sanctuary scholarship"]}],"id":[{"id":"10.13039\/501100000740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Current clinical tools for predicting relapse and guiding adjuvant therapy in clear cell renal cell carcinoma (ccRCC) lack precision, especially in intermediate-risk disease. This study evaluated whether a nonproliferative tumor cell phenotype, P21 (CDKN1A inhibitor)\u2013positive and MCM2 (DNA replication protein)\u2013negative (P21+\/MCM2\u2212), could serve as a robust biomarker to improve prognostic stratification and guide postnephrectomy treatment decisions. We used multiplex immunofluorescence and Artificial Intelligence\u2013based image analysis on nephrectomy specimens from three independent ccRCC cohorts: UK arm of the SORCE trial (n = 382), Korean (n = 71), and Scottish (n = 88). An optimal 2% cutoff for P21+\/MCM2\u2212 cells was determined using X-tile software. Additional analyses assessed endoglin\/CD105 coexpression, paired primary\u2013metastatic samples (n = 41), and associations with adjuvant sorafenib therapy. In two intermediate-risk ccRCC cohorts (SORCE, n = 63; Korean, n = 71), patients with &amp;gt;2% P21+\/MCM2\u2212 cells had significantly longer time to relapse [HR = 0.17; 95% confidence interval (CI), 0.06\u20130.54; HR = 0.27; 95% CI, 0.10\u20130.72]. Prognostic value was confirmed in high-risk (SORCE, HR = 0.43; 95% CI, 0.19\u20130.99) and all-risk (Scottish, HR = 0.37; 95% CI, 0.14\u20130.98) cohorts. Notably, patients with high P21+\/MCM2\u2212 levels on placebo fared better than those receiving adjuvant TKI therapy (HR = 0.29; 95% CI, 0.16\u20130.50). In 41 paired samples, 85% showed higher P21+\/MCM2\u2212 abundance in metastases than in primary tumors. As a conclusion, P21+\/MCM2\u2212 cell count is a robust biomarker that refines relapse risk stratification in ccRCC and identifies patients who may not benefit from adjuvant tyrosine kinase inhibitor (TKI) therapy. High levels of these nonproliferative, senescent-like cells suggest tumor dormancy and a more favorable outcome without treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>After surgery for clear cell renal cell carcinoma, relapse risk and benefit from adjuvant therapy remain uncertain. We identify a distinct P21+\/MCM2\u2212 tumor phenotype, nonproliferative and senescent-like, linked to favorable outcomes. Across three cohorts, &amp;gt;2% of these cells reduced relapse risk, but benefit was lost with adjuvant TKIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0805","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:45:58Z","timestamp":1776368758000},"page":"1061-1070","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiplexed P21\/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor\u2013Resistant Patients in Clear Cell Renal Cell Carcinoma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3476-6258","authenticated-orcid":false,"given":"Hazem","family":"Abdullah","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wn5qz54","id-type":"ROR","asserted-by":"publisher"}],"name":"University of St Andrews 1 School of Medicine, , St Andrews, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-4292","authenticated-orcid":false,"given":"In Hwa","family":"Um","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wn5qz54","id-type":"ROR","asserted-by":"publisher"}],"name":"University of St Andrews 1 School of Medicine, , St Andrews, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3188-9140","authenticated-orcid":false,"given":"Grant D.","family":"Stewart","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013meh722","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cambridge 2 Department of Surgery, , Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-5019","authenticated-orcid":false,"given":"Chang Wook","family":"Jeong","sequence":"additional","affiliation":[{"name":"3Department of Urology, Seoul National University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1987-2111","authenticated-orcid":false,"given":"Cheol","family":"Kwak","sequence":"additional","affiliation":[{"name":"3Department of Urology, Seoul National University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1969-8360","authenticated-orcid":false,"given":"Kyung Chul","family":"Moon","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-025X","authenticated-orcid":false,"given":"Alexander","family":"Laird","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009kr6r15","id-type":"ROR","asserted-by":"publisher"}],"name":"Western General Hospital 5 Department of Urology, , Edinburgh, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-292X","authenticated-orcid":false,"given":"Elena","family":"Frangou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/001mm6w73","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical Research Council Clinical Trials Unit at University College London (UCL) 6 , Institute of Clinical Trials and Methodology, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9663-4873","authenticated-orcid":false,"given":"Tim","family":"Eisen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013meh722","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cambridge 7 Department of Oncology, , Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6424-0554","authenticated-orcid":false,"given":"Angela","family":"Meade","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/001mm6w73","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical Research Council Clinical Trials Unit at University College London (UCL) 6 , Institute of Clinical Trials and Methodology, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-9988","authenticated-orcid":false,"given":"David J.","family":"Harrison","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02wn5qz54","id-type":"ROR","asserted-by":"publisher"}],"name":"University of St Andrews 1 School of Medicine, , St Andrews, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026050705563839400_bib1","article-title":"Renal cell carcinoma: practice essentials, background, pathophysiology","author":"Sachdeva","year":"2022"},{"key":"2026050705563839400_bib2","volume-title":"GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0 [Internet]","author":"Ferlay","year":"2012"},{"key":"2026050705563839400_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(22)01059-5","article-title":"The multispeciality approach to the management of localised kidney cancer","volume":"400","author":"Stewart","year":"2022","journal-title":"Lancet"},{"key":"2026050705563839400_bib4","doi-asserted-by":"crossref","first-page":"216327","DOI":"10.1016\/j.canlet.2023.216327","article-title":"CD105 in the progression and therapy of renal cell carcinoma","volume":"570","author":"Oladejo","year":"2023","journal-title":"Cancer Lett"},{"key":"2026050705563839400_bib5","doi-asserted-by":"crossref","first-page":"643065","DOI":"10.3389\/fonc.2021.643065","article-title":"Review of prognostic expression markers for clear cell renal cell carcinoma","volume":"11","author":"Petitprez","year":"2021","journal-title":"Front Oncol"},{"key":"2026050705563839400_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1756287217713902","article-title":"Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence","volume":"9","author":"Rizzo","year":"2017","journal-title":"Ther Adv Urol"},{"key":"2026050705563839400_bib7","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1200\/JCO.20.01800","article-title":"Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial","volume":"38","author":"Eisen","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026050705563839400_bib8","doi-asserted-by":"crossref","first-page":"e000185","DOI":"10.1136\/esmoopen-2017-000185","article-title":"New treatment options for metastatic renal cell carcinoma","volume":"2","author":"Rodriguez-Vida","year":"2017","journal-title":"ESMO Open"},{"key":"2026050705563839400_bib9","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3390\/cancers12082134","article-title":"Senescence and cancer: a review of clinical implications of senescence and senotherapies","volume":"12","author":"Wyld","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026050705563839400_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","article-title":"Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage","volume":"42","author":"Karimian","year":"2016","journal-title":"DNA Repair (Amst)"},{"key":"2026050705563839400_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.juro.2006.08.073","article-title":"p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches","volume":"177","author":"Weiss","year":"2007","journal-title":"J Urol"},{"key":"2026050705563839400_bib12","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1200\/JCO.1998.16.3.1197","article-title":"Role of the p16 tumor suppressor gene in cancer","volume":"16","author":"Liggett","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026050705563839400_bib13","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1091\/mbc.e11-10-0884","article-title":"Lamin B1 loss is a senescence-associated biomarker","volume":"23","author":"Freund","year":"2012","journal-title":"Mol Biol Cell"},{"key":"2026050705563839400_bib14","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.1073\/pnas.0403410101","article-title":"Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases","volume":"101","author":"Cortez","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050705563839400_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5114\/pjp.2020.103714","article-title":"Clinical utility of MCM2 and CD44 expression in clear cell renal cell carcinoma","volume":"71","author":"Gayyed","year":"2020","journal-title":"Polish J Pathol"},{"key":"2026050705563839400_bib16","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1158\/1078-0432.CCR-04-1776","article-title":"Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma","volume":"11","author":"Dudderidge","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2026050705563839400_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cncr.23566","article-title":"Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers","volume":"113","author":"Crispen","year":"2008","journal-title":"Cancer"},{"key":"2026050705563839400_bib18","first-page":"1","article-title":"Surveillance strategies for renal cell carcinoma patients following nephrectomy","volume":"8","author":"Chin","year":"2006","journal-title":"Rev Urol"},{"key":"2026050705563839400_bib19","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.21037\/atm.2018.12.46","article-title":"Predicting aggressive behavior in small renal tumors prior to treatment","volume":"6","author":"Shapiro","year":"2018","journal-title":"Ann Transl Med"},{"key":"2026050705563839400_bib20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41598-024-84620-9","article-title":"Expression pattern of cancer-associated cellular senescence genes in clear cell renal cell carcinoma distinguishes tumor subclasses with clinical implications","volume":"15","author":"Zhu","year":"2025","journal-title":"Sci Rep"},{"key":"2026050705563839400_bib21","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"key":"2026050705563839400_bib22","doi-asserted-by":"crossref","first-page":"e60483","DOI":"10.1371\/journal.pone.0060483","article-title":"Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome","volume":"8","author":"Laird","year":"2013","journal-title":"PLoS One"},{"key":"2026050705563839400_bib23","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026050705563839400_bib24","volume-title":"R: the R project for statistical computing","year":"2025"},{"key":"2026050705563839400_bib25","first-page":"2283","article-title":"Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy","volume":"31","author":"Nassiri","year":"2011","journal-title":"Anticancer Res"},{"key":"2026050705563839400_bib26","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2026050705563839400_bib27","first-page":"230","article-title":"MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway","volume":"44","author":"Wang","year":"2022","journal-title":"Yi Chuan"},{"key":"2026050705563839400_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41580-020-00314-w","article-title":"Cellular senescence in ageing: from mechanisms to therapeutic opportunities","volume":"22","author":"Di Micco","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026050705563839400_bib29","doi-asserted-by":"crossref","first-page":"645593","DOI":"10.3389\/fcell.2021.645593","article-title":"Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype","volume":"9","author":"Kumari","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026050705563839400_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12943-024-02096-7","article-title":"Cellular senescence and SASP in tumor progression and therapeutic opportunities","volume":"23","author":"Dong","year":"2024","journal-title":"Mol Cancer"},{"key":"2026050705563839400_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/modpathol.3800034","article-title":"Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer","volume":"17","author":"Saad","year":"2004","journal-title":"Mod Pathol"},{"key":"2026050705563839400_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41569-022-00739-0","article-title":"Mechanisms and consequences of endothelial cell senescence","volume":"20","author":"Bloom","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026050705563839400_bib33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4161\/cbt.12.9.17680","article-title":"Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy","volume":"12","author":"Inoue","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"2026050705563839400_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jsps.2021.12.004","article-title":"Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells","volume":"30","author":"As Sobeai","year":"2022","journal-title":"Saudi Pharm J"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0805\/3772425\/crc-25-0805.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1061\/3792688\/crc-25-0805.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1061\/3792688\/crc-25-0805.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:56:53Z","timestamp":1778147813000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/5\/1061\/785074\/Multiplexed-P21-MCM-2-Detection-Predicts-Relapse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0805","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8541987","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32702067","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702079","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702052","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702085","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702064","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702076","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702082","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702061","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}